Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

When looking at the stock market right now, the increasingly obvious question is to paraphrase that catchy 1940s tune: “Is you is, or is you ain’t, in a bubble?” ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Some of ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Here's a question with trillion-dollar consequences for the economy. Are we in an AI bubble or not? Planet Money's Jeff Guo runs us through some of the signs economists are looking for to get an ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Everyone in tech agrees we’re in a bubble. They just can’t agree on what it looks like — or what happens when it pops. MIT Technology Review Explains: Let our writers untangle the complex, messy world ...

Three Harvard faculty said they think fears that an artificial intelligence bubble will burst — leading stock prices to collapse in the wake of soaring investments into AI companies — are overblown ...